Procare Health appoints Kainjoo for a Commercial Growth Program and Digital Transformation Plan
Procare Health has appointed Kainjoo as a strategic partner for a Commercial Growth Program and Transformation Plan spanning headquarters and affiliates across Europe and the United States.
Read More
Anne-Marie Vernier on the consultant mindset: diagnose first, design second, deliver always
That mission shapes how we define a consultant. At Kainjoo, a consultant diagnoses brand-tech issues and designs solutions that teams can adopt with confidence. Anne-Marie Vernier embodies that definition with a grounded, decision-led approach that turns ambiguity into a clear path.
Read More
Evelyne Filip: the client-seat perspective powering global rollouts
Evelyne joined Kainjoo after working with us while she was client-side at OM Pharma. She also saw first-hand the Kainjoo transformation at Ferring between 2017 and 2021, during the period when Haider Alleg headed the global digital team.
Read More
Armine Kerdoun on Medical Affairs at Kainjoo .life: credibility as a growth engine
Kainjoo .life runs on a simple idea: strong brand experiences thrive when science, systems, and delivery move together. In life sciences, credibility shapes every decision. That credibility lives in language, evidence, governance, and the everyday rhythm of how teams ship work. That is where Armine Kerdoun, Medical Affairs Lead at Kainjoo .life, makes a measurable difference. She brings Medical Affairs into the heart of brand-tech consulting, ensuring digital journeys stay compelling, accurate, and ready for multi-stakeholder confidence.
Read More
Why Pharma's AI Playbook Looks Nothing Like Fintech's
AI is generating seismic shifts across regulated industries. While fintech leans on...
Read More
Ipsen's Strategic Transformation: A Comprehensive Case Study
David Loew took over as CEO of Ipsen during a turbulent period marked by a 70% drop in share price due to the FDA’s hold on palovarotene, a drug for a rare bone disease. Concurrently, their flagship product, Somatuline, faced new generic competition, and the company’s R&D pipeline was heavily skewed towards late-stage assets, posing significant challenges.
Read More